{
  "extraction_metadata": {
    "timestamp": "2025-10-04T13:57:53.185664",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to progression of the tumor, time to deterioration, intraoperative complications, mortality, morbidity, adverse events, neurotoxicity",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, recurrence, delay of recurrence, adverse events (general), quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2963
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to progression of the tumor, time to deterioration, intraoperative complications, mortality, morbidity, adverse events, neurotoxicity",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, complications, long-term survival, 5-year survival, recurrence, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2057
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, median survival, prognosis (BCLC staging system), adverse events, long-term treatment-related complications, therapeutic efficacy, recurrence, liver function, performance status (ECOG/PS), Child–Pugh class, albumin-bilirubin (ALBI), model for end-stage liver disease (MELD), response rates, tumor burden, portal invasion, extrahepatic spread",
      "ChunksUsed": 12,
      "ContextTokens": 2639
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding, side-effects (general)",
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, overall survival, response rates (RECIST criteria), adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 3575
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "improved survival, response rates, rebleeding prophylaxis, liver-related morbidity, mortality, adverse events, safety, cost-effectiveness, false positives, hypersensitivity to monitoring, prognosis (Child-Pugh score), prognosis (MELD score), prognosis (CLIP score), prognosis (BCLC staging classification), severe adverse events, donor morbidity, down-staging, early diagnosis, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 3023
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, adverse events, adverse events (Grade ≥ 3), quality of life, overall quality of life (measured with a validated and reliable instrument), local tumour control, success rate (downstaging/bridging), complications, distress, physical complaints, psychological complaints, psychosocial complaints, general complaints, early detection of recurrence, alpha-fetoprotein (AFP) monitoring",
      "ChunksUsed": 12,
      "ContextTokens": 2916
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "response rates (RECIST criteria), response rates (mRECIST), response rates (RECIS systems), response rates (multiphase computed tomography with contrast), response rates (magnetic resonance imaging with contrast), perioperative mortality, adverse events, overall survival, time to progression, effectiveness of ablation (multiphase computed tomography with contrast), effectiveness of ablation (magnetic resonance imaging), effectiveness of ablation (ultrasonography not appropriate), bridging therapy benefit (time to progression), histological and prognostic parameters, immunohistochemical confirmation of hepatocytic origin, genetic subtype identification",
      "ChunksUsed": 12,
      "ContextTokens": 2703
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "EORTC QLQ-C30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, survival, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2045
    }
  }
}